Post-marketing Surveillance Study for Verquvo (Vericiguat) in Korean Heart Failure Patients With Reduced Ejection Fraction
Latest Information Update: 02 May 2025
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 19 Dec 2023 Status changed from not yet recruiting to recruiting.
- 30 Nov 2023 New trial record